Stockscreener 앱 받기
1.64
3.53%
-0.06
전일 마감가:
$1.70
열려 있는:
$1.69
하루 거래량:
122.25K
Relative Volume:
0.31
시가총액:
$5.95M
수익:
-
순이익/손실:
$-15.47M
주가수익비율:
-3.28
EPS:
-0.5
순현금흐름:
$-13.51M
1주 성능:
-12.30%
1개월 성능:
-22.64%
6개월 성능:
+14.69%
1년 성능:
-67.72%
1일 변동 폭
$1.62
$1.74
1주일 범위
$1.45
$1.8595
52주 변동 폭
$1.30
$5.6432
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
NLSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.655 | 7.57M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.21 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
484.24 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.28 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
830.49 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.93 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nls Pharmaceutics Ltd 주식(NLSP)의 최신 뉴스
NLS Pharmaceutics’ (NLSP) Sell (E+) Rating Reaffirmed at Weiss Ratings - Defense World
Is NLS Pharmaceutics AG Equity Warrant stock reversal real or fakeEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Will NLS Pharmaceutics AG Equity Warrant stock outperform value stocksQuarterly Growth Report & Community Verified Trade Signals - newser.com
Custom watchlist performance reports with NLS Pharmaceutics AG Equity Warrant2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
Visualizing NLS Pharmaceutics AG stock with heatmaps2025 Price Momentum & Short-Term Swing Trade Alerts - newser.com
NLS Pharmaceutics AG Stock Analysis and ForecastCandlestick Pattern Analysis & Small Budget Investment Tips - earlytimes.in
Why NLS Pharmaceutics AG Equity Warrant stock is recommended by analystsJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Regression analysis insights on NLS Pharmaceutics AG Equity Warrant performanceJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
Combining machine learning predictions for NLS Pharmaceutics AGJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
What indicators show strength in NLS Pharmaceutics AG Equity WarrantJuly 2025 Sentiment & Stock Portfolio Risk Management - newser.com
Can a trend reversal in NLS Pharmaceutics AG lead to recoveryWeekly Stock Analysis & Free Community Supported Trade Ideas - newser.com
Is NLS Pharmaceutics AG a candidate for recovery playEarnings Overview Summary & Smart Money Movement Alerts - newser.com
Analyzing recovery setups for NLS Pharmaceutics AG Equity Warrant investors2025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
NLS Pharmaceutics files financial statements related to Kadimastem merger By Investing.com - Investing.com Nigeria
Will NLS Pharmaceutics AG Equity Warrant rebound enough to break evenGold Moves & Real-Time Stock Entry Alerts - newser.com
NLS Pharmaceutics files financial statements related to Kadimastem merger - Investing.com India
NLS Pharmaceutics Announces Strategic Merger with Kadimastem - TipRanks
Will NLS Pharmaceutics AG Equity Warrant bounce back from current supportQuarterly Trade Report & Real-Time Volume Analysis Alerts - newser.com
What’s next for NLS Pharmaceutics AG Equity Warrant stock priceQuarterly Earnings Report & Reliable Price Breakout Signals - newser.com
What to expect from NLS Pharmaceutics AG Equity Warrant in the next 30 daysJuly 2025 Rallies & AI Driven Stock Reports - newser.com
How NLS Pharmaceutics AG stock reacts to Fed rate cutsJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
Is NLS Pharmaceutics AG stock positioned well for digital economyWeekly Trend Recap & Technical Pattern Based Signals - newser.com
NLS Pharmaceutics Approve Merger with Kadimastem - citybiz
NLS Pharmaceutics stock tumbles after merger approval with Kadimastem By Investing.com - Investing.com Nigeria
NLS Pharmaceutics stock tumbles after merger approval with Kadimastem - Investing.com
NLSP Stock Faces Highs and Lows: A Closer Look - StocksToTrade
NLS Pharmaceutics Stock: What’s Next? - timothysykes.com
NLS Pharmaceutics shareholders approve merger with Kadimastem By Investing.com - Investing.com Australia
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem - TipRanks
NLS Pharmaceutics shareholders approve merger with Kadimastem - Investing.com India
NLS Pharmaceutics shareholders approve merger with Kadimastem and related proposals at extraordinary general meeting - MarketScreener
84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline - Stock Titan
Is NLS Pharmaceutics AG stock dividend yield sustainableWeekly Risk Summary & High Yield Equity Trading Tips - newser.com
NLS Pharmaceutics (NASDAQ:NLSP) Rating Increased to Hold at Wall Street Zen - Defense World
Visual trend scoring systems applied to NLS Pharmaceutics AG Equity WarrantJuly 2025 Price Swings & Accurate Buy Signal Alerts - newser.com
Using economic indicators to assess NLS Pharmaceutics AG Equity Warrant potentialWeekly Risk Summary & Scalable Portfolio Growth Methods - newser.com
Is NLS Pharmaceutics AG stock ready for a breakoutTrade Analysis Summary & Weekly High Return Stock Opportunities - newser.com
Market reaction to NLS Pharmaceutics AG Equity Warrant’s recent newsJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Custom strategy builders for tracking NLS Pharmaceutics AGMarket Performance Report & AI Enhanced Market Trend Forecasts - newser.com
Rally Mode: Does NLS Pharmaceutics AG stock benefit from AI growthPrice Action & Low Risk Growth Stock Ideas - خودرو بانک
NLS Pharmaceutics Engages New Accounting Firm After Marcum’s Resignation - The Globe and Mail
Nls Pharmaceutics Ltd (NLSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.45%
0.76%
자본화:
|
볼륨(24시간):